Immune cell signaling pathways involved in T-cell activation and cytokine modulation

Immune cell signaling pathways involved in T-cell activation and cytokine modulation represent the complex network of molecular interactions required for T-lymphocytes to recognize antigens and execute effector functions. This process typically initiates with the T-cell receptor (TCR) complex binding to an antigen-MHC complex, which, alongside co-stimulatory signals like CD28, triggers intracellular cascades involving kinases such as Lck and ZAP-70 (Smith-Garvin et al., 2009, Annu Rev Immunol). These cascades activate key transcription factors, including NFAT, NF-κB, and AP-1, leading to the production of cytokines like IL-2 that drive clonal expansion (Katzman et al., 2021, StatPearls). Cytokine modulation further occurs through the JAK/STAT pathway, which directs the differentiation of T-cells into specific subsets such as Th1, Th2, or Th17 (Seif et al., 2017, Cell Commun Signal). Dysregulation of these pathways is a hallmark of autoimmune disorders, chronic inflammation, and the immune evasion strategies employed by tumors (Sharpe & Pauken, 2018, Nat Rev Immunol). Consequently, these pathways are major therapeutic targets for immunosuppressants, anti-inflammatory drugs, and cancer immunotherapies like checkpoint inhibitors (Waldman et al., 2020, Nat Rev Immunol). Because this entry describes a broad biological process rather than a single molecular entity, it is classified as an incorrect target designation for structured drug-target mapping.

Other names

T-cell receptor (TCR) signaling pathwayT-lymphocyte activation cascadeCo-stimulation and cytokine signaling pathwaysAdaptive immune response signaling

Inhibition of calcineurin to prevent NFAT translocation; blockade of co-stimulatory signals (CTLA-4 Ig); inhibition of mTOR; blockade of immune checkpoints (PD-1/CTLA-4); and inhibition of Janus kinases (JAK) to prevent STAT-mediated cytokine signaling.